In addition, in vitro studies on pVHL −/− ccRCC cell lines indicate that Tempol, a stable nitroxide, has potential therapeutic activity against HIF-2α [254]. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.